Alliance Pharma Regulatory News (APH)

17 December 2015

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.

ALLIANCE PHARMA PLC

Completion of Acquisition and Placing, Re-admission and Director Shareholding

Alliance Pharma plc (AIM: APH) ("Alliance" or the "Company"), the specialty pharmaceutical company, today announces that the acquisition of the Healthcare Products Business from Sinclair IS Pharma plc (the "Acquisition") and the placing to part fund the Acquisition have completed and that the Company's enlarged issued share capital has been re-admitted to trading on AIM.

Accordingly, the Company now has 468,179,146 ordinary shares in issue and admitted to trading on AIM. Alliance does not hold any shares in treasury. This figure of 468,179,146 ordinary shares may be used by shareholders in the Company to determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 Director Shareholding

The Company also announces that Andrew Smith, Non-executive Chairman of the Company, has purchased 75,000 ordinary shares in the Company at a price of 41 pence per share pursuant to the broker option exercised by Numis Securities Limited as announced on 3 December 2015. Following this transaction, Mr Smith's total beneficial interest in the Company is 275,000 ordinary shares representing 0.06% of the Company's issued share capital.

Further information: